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Background: To analyse the overall clinical outcome and beneﬁts by applying protocol based image
guided adaptive brachytherapy combined with 3D conformal external beam radiotherapy (EBRT) ± che-
motherapy (ChT).
Methods: Treatment schedule was EBRT with 45–50.4 Gy ± concomitant cisplatin chemotherapy plus
4  7 Gy High Dose Rate (HDR) brachytherapy. Patients were treated in the ‘‘protocol period’’ (2001–
2008) with the prospective application of the High Risk CTV concept (D90) and dose volume constraints
for organs at risk including biological modelling. Dose volume adaptation was performed with the aim of
dose escalation in large tumours (prescribed D90 > 85 Gy), often with inserting additional interstitial nee-
dles. Dose volume constraints (D2cc) were 70–75 Gy for rectum and sigmoid and 90 Gy for bladder.
Late morbidity was prospectively scored, using LENT/SOMA Score. Disease outcome and treatment
related late morbidity were evaluated and compared using actuarial analysis.
Findings: One hundred and ﬁfty-six consecutive patients (median age 58 years) with cervix cancer FIGO
stages IB–IVA were treated with deﬁnitive radiotherapy in curative intent. Histology was squamous cell
cancer in 134 patients (86%), tumour size was >5 cm in 103 patients (66%), lymph node involvement in 75
patients (48%). Median follow-up was 42 months for all patients.
Interstitial techniques were used in addition to intracavitary brachytherapy in 69/156 (44%) patients.
Total prescribed mean dose (D90) was 93 ± 13 Gy, D2cc 86 ± 17 Gy for bladder, 65 ± 9 Gy for rectum
and 64 ± 9 Gy for sigmoid.
Complete remission was achieved in 151/156 patients (97%). Overall local control at 3 years was 95%; 98%
for tumours 2–5 cm, and 92% for tumours >5 cm (p = 0.04), 100% for IB, 96% for IIB, 86% for IIIB. Cancer
speciﬁc survival at 3 years was overall 74%, 83% for tumours 2–5 cm, 70% for tumours >5 cm, 83% for
IB, 84% for IIB, 52% for IIIB. Overall survival at 3 years was in total 68%, 72% for tumours 2–5 cm, 65%
for tumours >5 cm, 74% for IB, 78% for IIB, 45% for IIIB.
In regard to late morbidity in total 188 grade 1 + 2 and 11 grade 3 + 4 late events were observed in 143
patients. G1 + 2/G3 + 4 events for bladder were n = 32/3, for rectum n = 14/5, for bowel (including sig-
moid) n = 3/0, for vagina n = 128/2, respectively.
Interpretation: 3D conformal radiotherapy ± chemotherapy plus image (MRI) guided adaptive intracavi-
tary brachytherapy including needle insertion in advanced disease results in local control rates of
95–100% at 3 years in limited/favourable (IB/IIB) and 85–90% in large/poor response (IIB/III/IV) cervix
cancer patients associated with a moderate rate of treatment related morbidity. Compared to the
historical Vienna series there is relative reduction in pelvic recurrence by 65–70% and reduction in major
morbidity. The local control improvement seems to have impact on CSS and OS. Prospective clinical
multi-centre studies are mandatory to evaluate these challenging mono-institutional ﬁndings.
 2011 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.adiotherapy, Comprehensive
eneral Hospital of Vienna, 18-
ichard.poetter@meduniwien.
nder CC BY-NC-ND license.Radiotherapy and Oncology 100 (2011) 116–123Progress in radiation technology has been signiﬁcant during the
last decades in regard to imaging, treatment planning, and various
forms of advanced dose delivery, e.g. Intensity Modulated and
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ments on the daily process of planning and performance of exter-
nal beam radiotherapy has been dramatic [4,5]. However, the
clinical evidence for an improvement of outcome has been rather
limited, due to various reasons [3].
Similar developments have taken place in brachytherapy. In
gynaecology this has been mainly related to cervix cancer with
the integration of (repetitive) 3D imaging (MRI) into the treatment
planning process which had to be changed completely with the
introduction of an adaptive target concept and a dose volume
assessment balancing constraints for CTV and OAR [6,7]. The imag-
ing modality of choice has become MRI with also some place for CT
and maybe in future also for US [8,9]. Best technical improvements
so far have been mainly the adaptation of classical applicators to
become CT and MRI compatible and more recently the combina-
tion of intracavitary brachytherapy with a guided and focussed
interstitial approach (Vienna ring applicator, [10–12], Utrecht
ovoid applicator [12]).
These changes in brachytherapy technology seem to have a ma-
jor direct impact on clinical outcome [13]. For cervix cancer, in the
past major improvements in regard to loco-regional, distant con-
trol and survival has been achieved through simultaneous che-
mo-radiotherapy which became standard of care in 1999, when
ﬁve randomized trials were published [14–18]. However, accord-
ing to a recent joint and balanced meta-analysis of these trial
groups the absolute beneﬁt is pronounced, but limited which is
in particular true for advanced disease [19]. The absolute beneﬁt
for overall survival, disease free survival and local control at ﬁve
years has been estimated as 6%, 8%, and 9%, respectively, which
is well in line with what has been shown for other cancer sites,
e.g. head and neck [20]. The absolute overall survival beneﬁt is
largest for limited disease (I/IIA) with 10% and decreases in more
advanced stage with 7% for IIB and 3% for III/IVA. These ﬁndings
imply a signiﬁcant need for further improvement, which may be-
come possible through introduction of more intensive (adjuvant)
chemotherapy [21], but also through improvements of radiother-
apy, in particular for more advanced disease.
The signiﬁcant improvements of brachytherapy and EBRT
technology during the last decades have not resulted in obvious
major overall improvements in clinical outcome for cervical can-
cer according to what has been published, e.g. in the annual
treatment reports, in regard to overall survival [22] and accord-
ing to published mono-institutional series [23–25]. Nevertheless,
major differences have been reported between different brachy-
therapy traditions for certain clinical scenarios, e.g. stage III,
[23,25–29].
Favourable outcome after IGABT combined with 3D conformal
external beam radiotherapy ± chemotherapy has been recently re-
ported within the frame of some limited mono-institutional series
applying different treatment schedules [13,30–33]. IGABT seems
to play a major role in the improvement of clinical outcome, in par-
ticular of local control in advanced cervical cancer with no increase
in treatment related morbidity based on this mono-institutional
experience. The large Vienna clinical series on a consecutive num-
ber of 145 patients including the learning period published in
2007 has played a major role in elucidating the issue of improve-
ment of dose volume adaptation, dose escalation and clinical
outcome.
In order to further clarify the present and future clinical impact
of IGABT in cervical cancer, an analysis was performed to evaluate
the dosimetric parameters and overall clinical outcome in the
Vienna protocol period with applying the HR CTV concept and dose
volume constraints for OAR according to the later GEC ESTRO Rec-
ommendations in 156 consecutive patients with mature 3-year fol-
low-up data and to deﬁne the major clinical beneﬁts to be
expected from this new treatment method.Material and methods
Patient and tumour characteristics
A total of 218 consecutive patients with cervical cancer were re-
ferred for deﬁnitive radiotherapy to the Radiation Oncology
Department at the Vienna General Hospital between January
2001 and August 2008. For the current analysis, the following eli-
gibility criteria were applied: patients with stage IB1 to IVA dis-
ease, who underwent the complete deﬁnitive radiotherapy and
were followed in our department and who did not have a previous
history of malignancy. Sixty-two patients were ineligible for this
analysis: 30 with stage IVB disease, 5 as treated with palliative in-
tent, 7 as referred to our department only for BT, 7 due to prior or
simultaneous second malignancy (5 breast, 1 colon, 1 ovarian can-
cer); 13 patients due to incomplete radiotherapy for the following
reasons: 2 refused brachytherapy, 3 did not ﬁnish brachytherapy
because of missing compliance, 1 had progressive metastatic dis-
ease during EBRT, 4 interrupted treatment due to worsening med-
ical conditions, and 3 died during treatment (1 from sepsis and
pneumonia (no chemotherapy), 2 from cardiovascular disease).
One hundred and 56 patients with locally advanced cervical
cancer met the eligibility criteria and were thus available for anal-
ysis. All patients were treated with curative intent in the Depart-
ment of Radiotherapy applying a prospective in-house protocol
with High Risk CTV and dose volume constraints for organs at risk
(according to the Gyn GEC ESTRO Recommendations), with deﬁni-
tive radiotherapy consisting of 3D conformal external beam radio-
therapy (EBRT) ± concomitant chemotherapy and High-Dose-Rate
(HDR)-Brachytherapy. Median age was 58 years.
Patients were clinically staged according to the International
Federation of Gynaecology and Obstetrics (FIGO) criteria [34]: 12
stage IB1 (8%), 9 stage IB2 (6%), 4 stage IIA (3%), 88 stage IIB
(56%), 5 stage IIIA (3%), 32 stage IIIB (21%) and 6 stage IVA (4%).
Abdominal CT and pelvic MRI scans were performed in all patients,
in order to determine local, regional and abdominal tumour spread,
beside chest CT to rule out distant metastases. Tumour size as de-
ﬁned by clinical and MRI examination (maximum width) was 2–
5 cm in 53 patients (34%) andmore than 5 cm in 103 patients (66%).
One hundred thirty-four patients had squamous cell cancer
(86%), 14 had adenocarcinoma (9%), 5 had adenosquamous carci-
noma (3%) and 3 had other entities (2%). Ninety-six patients had
a pelvic laparoscopic lymph node assessment (62%) including the
removal of involved nodes. If this invasive procedure could not
be performed (60 patients, medical reasons: age, Karnofsky status),
CT and MRI were used to assess lymph node disease (size >1 cm,
loss of oval shape). In total, involved lymph nodes were detected
in 75 patients (48%). One hundred and fourteen patients (73%)
had concomitant chemotherapy, with 40 mg/m2 weekly cisplatin
(selection due to medical reasons).Treatment characteristics
For the detailed description of the general treatment and the
treatment planning characteristics we refer in particular to the
preceding report as published before recording the patient popula-
tion treated from 1998–2003 [13], but also to other publications
from the Vienna group describing these procedures in detail
[6,7,10,11,35–40]. In the following, speciﬁc issues are highlighted
which are of importance for the update of some treatment and
treatment planning parameters. In limited disease the treatment
schedule was changed during the protocol period to pelvic 3D EBRT
and 4  7 Gy HDR intracavitary brachytherapy. In patients with
common iliac lymph node involvement, para-aortic radiotherapy
was performed with a 3D conformal box technique (n = 37, 24%).
In 69 patients with unfavourable spread of residual disease at
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approach was used (44%) with the Vienna ring applicator in the
majority of cases, and some modiﬁcation in far advanced disease.
In 3 out of 156 patients, the MRI dataset was not sufﬁcient to
report meaningful DVH parameter. Dose volume constraints were
75 Gy in D2cc for rectum and sigmoid and 100 Gy for the bladder
in the beginning which were then gradually reduced to 70 Gy for
rectum and sigmoid, if feasible and 90 Gy for the bladder [38–
40]. Dose and target coverage were adapted (D90), considering
the institutional dose volume constraints for OAR. If appropriate
and feasible, the dose was escalated, especially in advanced disease
to arrive at a D90 of at least 85 Gy. For limited and good response
disease, the high dose in the HR CTV (>95 Gy D90) was not signif-
icantly reduced, only in case of violating dose volume constraints
for OAR. The median treatment time was 48 days.Endpoints
Patients were followed for disease related parameters and ad-
verse side effects every 3 months in the ﬁrst 2 years, in 6 month
intervals for the next 3 years and then annually. MRI was done
every 6 months in the ﬁrst 5 years.
Complete remission (CR) was deﬁned as no evidence of disease
3 months after end of treatment, evaluated by clinical examination
and MRI.
Pelvic failure was split in failure in true pelvis (cervix, uterine
corpus, vagina and parametria) and pelvis (additional pelvic
nodes).
Continuous complete remission (CCR) was deﬁned as no evi-
dence of disease after complete remission. It is subdivided in CCR
true pelvis (CCRtp) and CCR pelvis (CCRp).
Progression free survival (PFS) was deﬁned as no progression of
disease after tumour biopsy. PFS was subdivided in PFS true pelvis
(PFStp) deﬁned as local control, PFS pelvis (PFSp), deﬁned as local
and regional control, and PFS for distant metastases (PFSdm), de-
ﬁned as distant control, overall PFS is the freedom of local, regional
and distant failure.
Overall survival (OS) and cancer speciﬁc survival (CSS) were de-
ﬁned as the period from the date of biopsy until the date of death
and death by cervical cancer, respectively.
Late side effects are deﬁned as any side effect appearing earliest
91 days after the end of treatment and are prospectively scored
using the Late Effects in Normal Tissues-Subjective, Objective,
Management and Analytic score (LENT SOMA, G0: no side effects,
G4: worst side effect, LENT SOMA tables 1995). Side effects are re-
ported as absolute number of events for G1–G4 morbidity. In addi-
tion, actuarial rates are given for G3 and G4 morbidity.Statistical analysis and groups
Patients were analysed who underwent the complete deﬁnitive
radiotherapy treatment (see eligibility criteria). All parametersTable 1
Treatment response and site of relapse according to FIGO stage in 156 patients for the
parentheses ().
Stage Total no. Incomplete response True pelvic recurrence Pelvic lymph no
Central Non-central
IA 1 0 0 (0) 0 (0) 0 (0)
IB 21 0 0 (0) 0 (0) 1 (1)
IIA 3 0 0 (0) 0 (0) 0 (0)
IIB 88 2 0 (0) 1 (2) 1 (2)
IIIA 5 0 0 (0) 0 (0) 0 (0)
IIIB 32 2 0 (2) 2 (3) 2 (2)
IVA 6 1 0 (0) 0 (1) 0 (0)
Total 156 5 0 (2) 3 (6) 4 (5)were calculated for tumours 2–5 cm and tumours >5 cm and for
the different stages. For the calculation, the SPSS-program was
used (SPSS 15 for windows), applying the Kaplan–Meier method
and log rank test. Outcome parameters were calculated at 3 years.
Median follow up was 42 months for all patients and 58 months
for patients alive. Ten patients were lost to follow up.Results
Dose volume adaptation and dose escalation
ThemeanD90 ± 1SD for thewholepatient cohortwas93 ± 13 Gy,
it was 96 Gy ± 15 Gy for tumours 2–5 cm and 91 Gy ± 11 Gy for tu-
mours > 5 cm. In the period from 2001–2003 the mean D90 was
90 ± 15 Gy in total, with 94 ± 16 Gy for tumours 2–5 cm and
87 ± 14 Gy for tumours >5 cm. The mean D90 increased to
94 ± 10 Gy in the period from 2004–2008. The tumours 2–5 cm
had a mean D90 of 100 ± 10 Gy, and the large tumours > 5 cm a
mean D90 of 93 ± 9 Gy, respectively. For both tumour size groups
there was a mean 6 Gy increase in dose. Mean D2cc for bladder was
86 ± 17 Gy, 65 ± 9 Gy for rectum and 64 ± 9 Gy sigmoid.Disease control
A detailed overview on the different outcome parameters and
comparisons in regard to tumour size and stage of disease is given
in Tables 1–4 and in Fig. 1a–d with calculated values at a follow-up
time of 3 years.
Complete remission was achieved in 151/156 patients (97%).
Five patients had locally progressive disease. Recurrence in true
pelvis occurred in 8 patients, 3 simultaneously with distant metas-
tases. In addition, 5 patients had recurrence in the pelvic lymph
nodes. Thirty-four patients had distant metastases alone. The
events are shown in Tables 1 and 2.
Continuous complete remission for the true pelvis (CCRtp) was
97% at three years. For small tumours it was 98%, while for large
tumours CCRtp was 95%.
Overall actuarial local control (3y) was 95%; 98% for tumours 2–
5 cm, and 92% for tumours >5 cm (Table 2), 100% for IB, 96% for IIB,
and 86% for IIIB (Fig. 1b and d). Actuarial progression free survival
for distant metastases (3y) was 82% for all tumours, 87% for tu-
mours 2–5 cm, 78% for tumours >5 cm. According to tumour stage
it was 88% for IB, 85% for IIB, 69% for IIIB, 60% for IVA.
Ninety patients of the whole patient cohort were still alive at
the time of study (58%), 49 patients died because of cancer and
17 due to other reasons. Actuarial cancer speciﬁc survival (3y)
was 74% for all patients, 83% for tumours 2–5 cm, 70% for tumours
>5 cm, 83% for IB, 84% for IIB, 52% for IIIB (see Tables 2 and 4, Fig. 1a
and c). Actuarial overall survival (3y) was in total 68%, 72% for tu-
mours 2–5 cm, 65% for tumours >5 cm, 74% for IB, 79% for IIB, 45%
for IIIB (see Tables 2 and 4, Fig. 1a).period of interest (3 years); numbers for the whole observation period are given in
de recurrence Distant relapse alone Overall failure No evidence of disease
0 (0) 0 (0) 1 (1)
2 (3) 3 (4) 18 (17)
1 (1) 1 (1) 2 (2)
12 (15) 16 (21) 72 (67)
2 (2) 2 (2) 3 (3)
8 (11) 14 (20) 18 (12)
2 (2) 3 (4) 3 (2)
27 (34) 39 (52) 117 (104)
Table 2
Outcome for 156 patients treated with radiotherapy ± chemotherapy and image
guided adaptive brachytherapy. Events (n) at 3 years and after whole observation
period, patients per subgroup (n), actuarial estimates (%).
Protocol period image guided adaptive BT 2001–2008
Total n Events overall
period
n Events 3 year
period
%
3 years
PFStp (local control) 156 13 8 95
2–5 cm 53 1 1 98
>5 cm 103 12 7 92
PFSp (pelvic control) 156 18 12 91
2–5 cm 53 3 3 95
>5 cm 103 15 9 90
PFSdm (distant failure
free)
156 34 27 82
2–5 cm 53 9 6 87
>5 cm 103 25 21 78
PFSoverall (overall
failure free)
156 52 39 75
2–5 cm 53 12 8 83
>5 cm 103 40 31 70
Cancer speciﬁc
survival
156 49 37 74
2–5 cm 53 12 8 83
>5 cm 103 37 29 70
Overall survival 156 66 49 68
2–5 cm 53 22 16 72
>5 cm 103 44 33 65
PFS: progression free survival.
tp/p = True pelvis/pelvis (uterus, vagina, parametria/lymph nodes).
Table 3
Late adverse effects (LENT SOMA) after radiotherapy ± chemotherapy and image
guided adaptive brachytherapy in 156 patients (absolute numbers).
Late adverse effects Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
n n n n n
Vagina 23 84 44 2 1
Bladder 121 20 12 3 0
Rectum 137 8 6 2 3
Bowel/Sigmoid 152 2 2 0 0
Total 114 64 7 4
without vagina 30 20 5 3
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In regard to late morbidity altogether 188 grade 1 + 2 and 11
grade 3 + 4 events, respectively, were observed in 140 patients.
Sixteen patients did not develop any side effects. For details we re-
fer to Table 3.
Actuarial rate for G3 + G4 morbidity was 2%/3% for the bladder,
4%/4% for the rectum, 0%/0%, for the bowel and 1%/3% for the vagi-
na at 3/5 years, respectively.
Bladder
Twenty patients had grade 1 and 12 patients grade 2 side effects
(mainly urinary urgency and frequency). Three patients developed
grade 3 late side effects in the bladder (urinary frequency, urge).
Rectum
Eight patients experienced grade 1 and 6 patients grade 2 mor-
bidity (mainly urgency and bleeding). Two patients suffered from
massive rectal bleeding and also needed blood transfusions (G3).
Three patients underwent stoma surgery (G4): 1 patient had rectal
wall ulceration, 3–4 cm in diameter, which resulted in a ﬁstula to
the vagina, a second patient developed a recto-vaginal ﬁstula,
and a third patient rectal perforation.Table 4
Three year outcome in 418 patients after deﬁnitive radiotherapy ± chemotherapy in cervica
Medical University of Vienna.
3 Year-OS (%) 3 Year-CS
FIGO stage FIGO stag
No. of patients n = 418 IB IIB IIIB IVA IB IIB
Vienna: 1993–1997a 189 62 70 46 40 77 78
Vienna: 1998–2000b 73 80 61 12 25 80 71
Vienna: 2001–2008c 156 74 79 45 33 83 84
a Radiotherapy alone; CT assisted brachytherapy treatment planning.
b Radiotherapy ± chemotherapy; MRI guided adaptive brachytherapy: learning period
c Radiotherapy ± chemotherapy; MRI guided adaptive brachytherapy: protocol period
* Actuarial rates for G3/G4 morbidity (LENT-SOMA score).Bowel (including sigmoid)
Two patients developed grade 1 side effects suffering from mild
diarrhoea with frequency 2–3 times daily (G1) and one patient had
moderate diarrhoea up to 8 times daily (G2). No patient developed
grade 3 or 4 side effects.Vagina
Grade 1 side effects were seen in 84 patients and grade 2 in 44
patients (mainly adhesions, teleangiectasia, dyspareunia). Two pa-
tients developed irreversible obliteration of more than two-thirds
of the entire vaginal length (G3). One patient developed complete
obliteration of the vagina (G4).Discussion
The clinical impact of MRI assisted dose volume adapted brach-
ytherapy combined with 3D conformal EBRT ± cisplatin in locally
advanced cervix cancer, based on a large single-institution study
(n = 145), was ﬁrst reported in our previous publication divided
into a learning period and a subsequent protocol period following
the GEC ESTRO Recommendations prospectively [13]. There has
been some additional evidence with favourable outcome provided
from mono-institutional experience from IGR, Paris and Tata
Memorial, Mumbai with MRI guided deﬁnitive adaptive PDR/HDR
brachytherapy applying the GEC ESTRO Recommendations, in lim-
ited patient numbers, with no local recurrences in 45 patients (82%
stage IB2/II) and 3 in 24 patients, respectively [41,42]. The CT expe-
rience published so far (Addenbrooke, Pittsburgh, Seoul) has re-
vealed high local control rates (96%; 75%; 97%) in limited patient
numbers [31,33,43], with clear and signiﬁcant improvements com-
pared to historical controls, for example 96% vs. 76% and 97% vs
81% [31,33]. The Ultrasound experience also provides challenging
results [32]. The ﬁrst prospective multicentre trial (STIC, France)
comparing 2D to 3D CT image guided PDR brachytherapy in deﬁn-
itive radiotherapy at 2 years revealed a signiﬁcant improvement in
local control (74% vs. 79%) and a signiﬁcant reduction in treatment
related morbidity (G3/G4 14% vs. 1%) [44].l cancer patients treated from 1993–1997 [62], 1998–2000 [31] and 2001–2008 at the
S (%) 3 Year-PFS pelvis (%) 3Year-G3/G4 morbidity (%)*
e FIGO stage All stages
IIIB IVA IB IIB IIIB IVA Bladder Bowel/rectum Vagina
59 53 100 87 69 60 3 10 31
28 25 95 92 67 70 3 5 7
52 40 94 96 75 75 2 4 1
.
.
Fig. 1. Outcome after radiotherapy ± chemotherapy and image-guided adaptive brachytherapy. (a) Local control, cancer speciﬁc survival and overall survival for all 156
patients. (b) Local control and tumour size. (c) Cancer speciﬁc survival for FIGO stages IB, IIB, IIIB. (d) Local control for FIGO stages IB, IIB, IIIB.
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2003) [13] with mature 3-year data on the protocol period
(2001–2008) in a considerable number of 156 consecutive patients
treated up to the start of the large prospective multicentre EM-
BRACE study (http://www.embracestudy.dk). The results clearly
conﬁrm that excellent local control rates can be achieved through
MRI guided adaptive brachytherapy following a protocol according
to the concepts of the GEC ESTRO Recommendations, with an over-
all local control rate of 95% at 3 years including 103/156 (66%)
patients with tumour size >5 cm. For the large tumours alone,
the 3-year rate was 92%, for the tumours 2–5 cm 98%. This is an
outstanding treatment result, which has to our knowledge not
been achieved so far, neither in cervix cancer nor at any other tu-
mour sites for advanced solid tumours by deﬁnitive radio(-chemo-)
therapy alone. Local failures in this IGABT experience compare in
absolute numbers very favourably with Vienna historical series
for tumours >5 cm (Table 4): 7/103 (2001–2008) versus 12/40
(1998–2000, [13]) and 22/124 (1993–97, [45]).1 This evident
improvement was (mainly) in large tumours >5 cm, with actuarial
data for pelvic control raising from 67%/64% [13,45] in 124/40 pa-
tients to 90% in 103 patients.2 This translates into an absolute local
control beneﬁt of 23–26% (actuarial) and a relative reduction in local
failure of about 65% compared to the historical Vienna series. The
major contribution to this major improvement is attributed to the
change to MRI guidance with dose volume adaptation and dose esca-1 [Both published Vienna series (1998–2000: MRI learning period [13]; 1993–1997:
radiotherapy alone/CT assisted BT treatment planning [45] are taken for comparison,
as both together are considered to represent best the full picture of the treatment in
the preceding decade. The results from the period 1998–2000 were particularly poor].
2 [Actuarial pelvic control is given because the publication in 2000 only provides
actuarial pelvic control data, with the majority of events being local, 22/26 (Table 1
[45]). For the current series this is 7/8 pelvic failures being local, (Tables 1 and 2)].lation to a mean dose of 93 Gy for High Risk CTV (deﬁned according
to treatment response) and even much larger doses inside this HR
CTV, during 2001–2008 (D90). There may be also some contribution
through the introduction of simultaneous cisplatin chemotherapy in
1999 [46] as the beneﬁcial effect of radiochemotherapy on local con-
trol has been well described, however less pronounced in more ad-
vanced disease [19]. In the period 1993–1997, radiochemotherapy
was not applied, whereas in the recent series it was applied in
73%. The excellent regional control may be partly also attributable
to laparoscopic pelvic lymph node dissection with macroscopic re-
moval which was ﬁrst introduced in 1997 and performed in 62% of
patients in the recent series.
Current protocols on dose escalation in EBRT using advanced
(functional) imaging, treatment planning and delivery techniques
try to go into a similar direction aiming at the improvement of
local control through volume adaptation and dose escalation at
tumour sites where local failure is still very considerable, e.g. in
NSCLC [47] (new FP 7 protocol Amsterdam/Maastricht) and in head
and neck cancer [48]. In prostate cancer excellent results seem to
be clinically achievable and superior to ultra high dose IMRT when
implementing image guided prostate brachytherapy into treat-
ment protocols e.g. for intermediate risk prostate cancer [49],
underlining the beneﬁcial effect of very focussed dose escalation.
It has to be outlined that the recent cervix cancer experience re-
ported here as well as in some of the dose escalation techniques
brieﬂy mentioned try to deﬁne analogue new ways of dose pre-
scription which consist of balancing dose volume constraints for
OAR and for target volume aiming at achieving the highest target
dose as individually possible respecting the OAR dose volume
constraints.
Within the protocol period 2001–2008, there was also an
improvement in local control at 3 years for large tumours: 2001–
2003: 6 failures out of 38 (Table 2 [13]) versus 2004–2008:
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continuous improvement in dose volume adaptation and dose
escalation from mean 87 Gy in the ﬁrst part of the protocol period
to 93 Gy in the second part, also increasing the number of com-
bined intracavitary/interstitial applications.
In regard to stage of disease, the major beneﬁt is in advanced
disease. For stage IIB/IIIB there are only 3/4 events out of 88/32
patients with a 96%/86% actuarial rate at 3 years, respectively
(Fig. 1d). This compares very favourably with literature data
[25,28]. However, there are some late events after 3 years, 1 in
IIB and 4 in IIIB, however, mainly from the early protocol period.
This implies that the failure rate at 5 years for IIIB will considerably
drop (overall 8/32) and that there is obvious need for further
improvement of local control, in particular for this subset of IIIB
patients. Opposed to concomitant chemotherapy with local control
improvement of 7% for IIB and 3% for III/IVA [19], the effect of
image guided brachytherapy seems to be in fact most pronounced
in very advanced disease (tumours >5 cm) with an absolute local
control beneﬁt of 23–26% in the Vienna series.
The mean D90 of 90 Gy during 2001–2003 became mean D90 of
94 Gy during 2004–2008. It has to be kept in mind that the mean
D90 for tumours 2–5 cm has been 96 Gy for all patients, 94 Gy
for the ﬁrst period, 100 Gy for the second period, whereas for
tumours >5 cm the mean D90 has been 91 Gy for the whole period
and 87 Gy for the ﬁrst period and 93 Gy for the second period.
Although this dose increase with excellent local control supports
strongly the assumption of a dose effect for local control and
although dose volume effects could already be clearly shown for
advanced disease in the Vienna series [36,37], the large variation
of dose values underlines that there is so far only limited evidence
for well deﬁned absolute dose values to be applied for a given clin-
ical scenario (e.g. IB, IIB, IIIB). It also has to be taken into account
that the dose variation through the various mono-institutional ser-
ies with similar clinical outcome has been large so far [50–53].
Overall the clinical update from the recent Vienna series on
local control compares well with what has been reported so far
from partly smaller series with partly more limited follow up
[31–33,41–44] and indicates the large clinical beneﬁt to be ex-
pected in regard to local control from this new image guided adap-
tive approach, in particular for advanced disease.
The improved local control in tumours >5 cm seems to be asso-
ciated with some increase in cancer speciﬁc survival at 3 years
from 57%/40% in 1993–97/98–2000 [13,45] to 70% in 2001–2008,
respectively, whereas no change was detectable in tumours
2–5 cm. CSS (3y) is 77%/80% and 83% for stage IB, 78%/71% and
84% in stage IIB, 59%/28% and 52% in stage IIIB, in the historical
and recent periods, respectively (Table 4, Fig. 1c). These ﬁndings
may be interpreted as a trend to improved CSS, in particular for
not very far advanced disease (stage IIB), whereas this is not seen
in very advanced disease (stage IIIB). Such ﬁndings have clearly
to be further clariﬁed, also with longer follow up, as more events
after the 3-year period will follow. At present the impact of the
local image guided adaptive approach on cancer speciﬁc survival
is not straightforward and demands clearly prospective clinical
studies.
It is worthwhile to notice that morbidity was not increased in
the protocol period. The tendency is rather a decrease (Tables 3
and 4, compared to [13,45]). Severe morbidity (G3/G4) was low
despite a very high radiation dose in the HR CTV: for the bladder
the actuarial rate was 2%/3%, for the rectum 4%/4%, for the bowel
0%/0%, for the vagina 1%/3% at 3/5 years, respectively. This is in
accordance with the recent ﬁndings from the STIC trial [44].
There are limitations for these ﬁndings from the Vienna series:
the current clinical results were achieved within a single institu-
tional experience and are compared to a historical control of this
institution with all the well known critical implications forhistorical comparisons [compare footnote 2]. The prognostic vari-
ables and the staging procedures were not comprehensively eval-
uated (e.g. lymph nodes, histology), the prospective evaluation
focussed on tumour size, tumour volume and dose volume rela-
tions. The results may therefore be biased by such uncontrolled pa-
tient, tumour and staging parameters. The growing experience in
CT assisted and then MRI guided adaptive brachytherapy of the
Vienna investigators over more than 15 years is also a factor not
well controlled. Such limitations will be partly overcome in the
foreseeable future. A prospective collaborative International obser-
vational study on the parameters and the effects of MRI guided
brachytherapy in locally advanced cervical cancer (EMBRACE)
was initiated [54] and also a retrospective multi-institutional re-
view following the same principles for reporting (RetroEMBRACE).
These studies will altogether provide data on minimum 1200 pa-
tients treated with IGABT during the next years [55,56] in addition
to the data soon becoming available from a large prospective
French trial (STIC) [44].
Despite the growing importance of IGABT during the last years
and multiple research activities in the ﬁeld [32,33,39,40,52,53,57–
68], there are still major issues to be clariﬁed in order to bring
IGABT to the next more mature levels. The most important issues
are on DVH parameters and their correlation to outcome, both
for CTV and OAR. This is of particular interest for limited and more
advanced disease with good and poor response. The issue of dose
volume constraints has to be clariﬁed for the CTV, both for favour-
able and unfavourable advanced disease, with likely dose de-esca-
lation and escalation [69]. Furthermore, there is the dissemination
issue as IGABT is at present mainly linked to MRI with limited
availability in the western world and even less all over the world.
It has to be clariﬁed, to what extent imaging technologies like CT
and/or US will be efﬁcient enough to become an alternative and/
or a complementary tool within IGABT, next to MRI.
Despite the signiﬁcantly improved local control, the assumed
associated improvement in (cancer speciﬁc) survival needs to be
clariﬁed, also in the frame of chemoradiation [19]. Image guided
adaptive brachytherapy will reduce local failure signiﬁcantly,
which will further make distant metastases the predominant pat-
tern of failure (overall 52 with 34 distant compared to 18 loco-re-
gional in this series, Table 1). This needs new strategies to
overcome distant failure more efﬁciently which may be intensiﬁed
simultaneous chemo-radiotherapy [21] and/or adjuvant chemo-
therapy [70] and/or any form of ‘‘targeted therapies’’, in particular
for patients identiﬁed – based on poor prognostic factors – to be at
high risk of distant metastases. For future combined modality trials
in cervix cancer (cytotoxic chemotherapy, targeted therapies),
image guided adaptive brachytherapy should become a mandatory
integral part in order to take advantage of the large clinical impact
of this new treatment method in regard to local control and likely
also survival.
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